August 07, 2018 - Halozyme Therapeutics, Inc. (NASDAQ:HALO) has filed a financial statement reporting Earnings Per Share Basic of $-0 USD. Previously, on May 10, 2018, Halozyme Therapeutics, Inc. reported Earnings Per Share Basic of $-0 USD.

Period EndPeriodValue
2018-06-30 2018-Q2 -0.16
2018-03-31 2018-Q1 -0.19
2017-09-30 2017-Q3 0.02
2017-06-30 2017-Q2 -0.23
2017-03-31 2017-Q1 -0.26
2016-09-30 2016-Q3 -0.23
2016-06-30 2016-Q2 -0.21
2016-03-31 2016-Q1 -0.16
2015-09-30 2015-Q3 -0.19
2015-06-30 2015-Q2 0.02
2015-03-31 2015-Q1 -0.12
2014-09-30 2014-Q3 -0.16
2014-06-30 2014-Q2 -0.13
AccruedOutsourcedResearchAndDevelopmentExpensesCurrent AccruedOutsourcedResearchandDevelopmentExpensesLongTerm Accruedmanufacturingexpenses AllocatedShareBasedCompensationExpense CostsAndExpenses CurrentFederalTaxExpenseBenefit CurrentStateAndLocalTaxExpenseBenefit DeferredFederalIncomeTaxExpenseBenefit DeferredForeignIncomeTaxExpenseBenefit DeferredRevenue DeferredRevenueCurrent DeferredRevenueNoncurrent DeferredRevenueRelatingToUpfrontPaymentLicenseFees DeferredStateAndLocalIncomeTaxExpenseBenefit DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost HypotheticalLicenseRevenueunderASC606 HypotheticalRoyaltyRevenueunderASC606 IncomeTaxExpenseBenefit IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate IncomeTaxReconciliationNondeductibleExpenseOther IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost IncreaseDecreaseInDeferredRevenue IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets InterestExpense LicenseAndServicesRevenue OperatingLeasesRentExpenseNet OtherNoncashExpense OtherNonoperatingIncomeExpense OtherPrepaidExpenseCurrent PrepaidExpenseAndOtherAssets PrepaidExpenseAndOtherAssetsCurrent PrepaidExpenseAndOtherAssetsNoncurrent PrepaidExpenseCurrent RecognitionOfDeferredRevenue ResearchAndDevelopmentExpense Revenueamortizationoflicensepayments Revenues RoyaltyRevenue SalesRevenueGoodsNet SellingGeneralAndAdministrativeExpense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense ValuationAllowancesAndReservesChargedToCostAndExpense

Related News Stories

Halozyme Therapeutics (HALO) Reports Q2 Loss, Tops Revenue Estimates

2018-08-08 zacks
Halozyme Therapeutics (HALO - Free Report) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.23 per share a year ago. These figures are adjusted for non-recurring items. (2-0)

Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q2 2018 Results - Earnings Call Transcript

2018-08-08 seekingalpha
Good day, ladies and gentlemen and welcome to the Halozyme Investor Call. We now have all of have speakers in conference. Please be aware that your line is in listen-only mode. At the conclusion on today’s presentation, we will open the floor for questions, [Operator Instructions]. (4-0)

Alexion's (ALXN) Earnings Beat Estimates in Q2, Guidance Up

2018-07-26 zacks
Alexion Pharmaceuticals, Inc. (ALXN - Free Report) posted second-quarter 2018 adjusted earnings of $2.07 per share, which came in higher than the year-ago earnings of $1.56 by 32.7%. Earnings also beat the Zacks Consensus Estimate of $1.69. Strong product revenues drove the bottom line in the quarter. (1-0)

Biotech Analysis Central Pharma News: Celgene's Protocol Change, Roche's BLA For Herceptin, Amgen's Resubmission For Osteoporosis

2018-07-16 seekingalpha
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. (4-3)

Halozyme Therapeutics' (HALO) CEO Helen Torley on Q1 2018 Results - Earnings Call Transcript

2018-05-11 seekingalpha
Good afternoon and welcome to the Halozyme Therapeutics First Quarter 2018 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this call is being recorded. (52-0)

CUSIP: 40637H109